David Wirta

1.8k total citations
44 papers, 762 citations indexed

About

David Wirta is a scholar working on Ophthalmology, Public Health, Environmental and Occupational Health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David Wirta has authored 44 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Ophthalmology, 27 papers in Public Health, Environmental and Occupational Health and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David Wirta's work include Glaucoma and retinal disorders (28 papers), Ocular Surface and Contact Lens (26 papers) and Allergic Rhinitis and Sensitization (8 papers). David Wirta is often cited by papers focused on Glaucoma and retinal disorders (28 papers), Ocular Surface and Contact Lens (26 papers) and Allergic Rhinitis and Sensitization (8 papers). David Wirta collaborates with scholars based in United States, Japan and Canada. David Wirta's co-authors include Sonja Krösser, Kenneth Sall, David A. Weinberg, Norman Shorr, Robert A. Goldberg, Joseph B. Ciolino, George W Ousler, Harvey Dubiner, Joseph Tauber and Gail Torkildsen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Ophthalmology and American Journal of Ophthalmology.

In The Last Decade

David Wirta

39 papers receiving 743 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Wirta United States 17 426 366 213 146 109 44 762
Jutta Horwath‐Winter Austria 14 586 1.4× 313 0.9× 284 1.3× 177 1.2× 105 1.0× 36 750
Jimmy D. Bartlett United States 15 467 1.1× 432 1.2× 262 1.2× 105 0.7× 150 1.4× 31 817
Jason Bacharach United States 14 350 0.8× 723 2.0× 416 2.0× 101 0.7× 106 1.0× 39 962
Stefano Sebastiani Italy 13 416 1.0× 365 1.0× 344 1.6× 84 0.6× 61 0.6× 22 635
Michael Korenfeld United States 11 139 0.3× 196 0.5× 97 0.5× 52 0.4× 31 0.3× 21 417
K. Bjerrum Denmark 8 292 0.7× 155 0.4× 106 0.5× 56 0.4× 70 0.6× 23 500
Fatih Özçura Türkiye 13 284 0.7× 365 1.0× 267 1.3× 73 0.5× 61 0.6× 50 574
Giuseppe Ferreri Italy 14 362 0.8× 293 0.8× 318 1.5× 48 0.3× 58 0.5× 32 629
Mutlu Acar Türkiye 10 211 0.5× 120 0.3× 52 0.2× 111 0.8× 28 0.3× 28 371
G. Ertuğrul Mirza Türkiye 11 155 0.4× 191 0.5× 200 0.9× 22 0.2× 20 0.2× 23 387

Countries citing papers authored by David Wirta

Since Specialization
Citations

This map shows the geographic impact of David Wirta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wirta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wirta more than expected).

Fields of papers citing papers by David Wirta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wirta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wirta. The network helps show where David Wirta may publish in the future.

Co-authorship network of co-authors of David Wirta

This figure shows the co-authorship network connecting the top 25 collaborators of David Wirta. A scholar is included among the top collaborators of David Wirta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wirta. David Wirta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wirta, David, Shérif M. El-Harazi, Michael Tepedino, & Jason Bacharach. (2025). Sepetaprost 0.002% Noninferiority vs. Timolol 0.5% in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology Glaucoma. 8(4). 384–392.
2.
Pattar, Guruprasad R., David Wirta, Gary Jerkins, et al.. (2025). Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease. Ophthalmology.
3.
Pepose, Jay S., David Wirta, David Evans, et al.. (2024). Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution. Ophthalmology. 132(1). 79–91.
4.
Coleman, William P., Vince Bertucci, Shannon Humphrey, et al.. (2024). NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. Aesthetic Surgery Journal. 45(4). 404–413.
5.
González, Víctor H., et al.. (2023). Two Randomized, Double-masked, Placebo-controlled Studies of the Local Anesthetic Effect of Articaine Ophthalmic Solution. Clinical ophthalmology. Volume 17. 1357–1365.
6.
Sun, Yang, David Wirta, Vidhu Mathur, et al.. (2023). Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease. SHILAP Revista de lepidopterología. 3(2). 100290–100290. 16 indexed citations
7.
Wirta, David, et al.. (2023). Double-Masked, Vehicle-Controlled, Randomized, Phase II Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution. SHILAP Revista de lepidopterología. 4(2). 100426–100426. 2 indexed citations
8.
Wirta, David, Yasuaki Kuwayama, Fenghe Lu, Hui Shao, & Noriko Odani‐Kawabata. (2022). Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study. Journal of Ocular Pharmacology and Therapeutics. 38(3). 240–251. 9 indexed citations
9.
Craven, E. Randy, et al.. (2021). Corneal endothelial cell loss associated with selective laser trabeculoplasty. Investigative Ophthalmology & Visual Science. 62(8). 2561–2561. 1 indexed citations
10.
11.
Wirta, David, Gail Torkildsen, John Lonsdale, et al.. (2019). A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology. 126(6). 792–800. 56 indexed citations
12.
Weinreb, Robert N., Jason Bacharach, Robert D. Fechtner, et al.. (2018). 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%. Ophthalmology. 126(8). 1095–1104. 10 indexed citations
13.
Stacy, Rebecca C., Kenneth Huttner, James H. Peace, et al.. (2018). A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma. American Journal of Ophthalmology. 192. 113–123. 13 indexed citations
14.
Chen, Michelle Y., Kenneth Sall, Michael Tepedino, et al.. (2018). Patient-reported Outcomes of Bimatoprost Ocular Ring in an Open-label Extension Study in Patients with Open-angle Glaucoma or Ocular Hypertension. 59(9). 1231–1231. 1 indexed citations
15.
Dubiner, Harvey, et al.. (2017). Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clinical ophthalmology. Volume 11. 669–681. 10 indexed citations
16.
Brandt, James D., Harvey Dubiner, Kenneth Sall, et al.. (2017). Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring. Ophthalmology. 124(10). 1565–1566. 49 indexed citations
17.
Bruce, Suzanne, et al.. (2016). An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clinical ophthalmology. 10. 419–419. 24 indexed citations
18.
Brandt, James D., Kenneth Sall, Harvey Dubiner, et al.. (2016). Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Ophthalmology. 123(8). 1685–1694. 81 indexed citations
19.
Peace, James H., et al.. (2015). Polyquaternium-1–Preserved Travoprost 0.003% or Benzalkonium Chloride–Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension. American Journal of Ophthalmology. 160(2). 266–274.e1. 24 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jutta Horwath‐Winter Breakdown of academic impact, for papers by Jimmy D. Bartlett Breakdown of academic impact, for papers by Jason Bacharach Breakdown of academic impact, for papers by Stefano Sebastiani Breakdown of academic impact, for papers by Michael Korenfeld Breakdown of academic impact, for papers by K. Bjerrum Breakdown of academic impact, for papers by Fatih Özçura Breakdown of academic impact, for papers by Giuseppe Ferreri Breakdown of academic impact, for papers by Mutlu Acar Breakdown of academic impact, for papers by G. Ertuğrul Mirza
Rankless by CCL
2026